TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Valneva ( (VALN) ).
On August 25, 2025, Valneva announced that the FDA suspended the license for its chikungunya vaccine, IXCHIQ®, in the U.S. due to four new reports of serious adverse events. This suspension requires Valneva to halt the shipping and selling of IXCHIQ® in the U.S. The company is investigating these cases further and evaluating the potential financial impact of a permanent withdrawal of the vaccine’s license in the U.S. Despite this setback, Valneva remains committed to providing the vaccine globally, especially in chikungunya-endemic countries, and continues to engage with health authorities to maintain high safety standards.
The most recent analyst rating on (VALN) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score is driven by strong technical momentum and positive earnings call sentiment, despite financial performance challenges and a weak valuation. The company’s strategic advances in vaccine development and revenue growth provide a positive outlook, but profitability and cash flow issues need addressing.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases that address unmet medical needs. The company has a strong track record of advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines. Valneva is also working on vaccine candidates against Lyme disease, Shigella, Zika virus, and other global public health threats.
Average Trading Volume: 44,981
Technical Sentiment Signal: Buy
Current Market Cap: $1B
See more insights into VALN stock on TipRanks’ Stock Analysis page.